In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Antimicrobial Agents and Chemotherapy
Catharine C BulikDavid P Nicolau

Abstract

We describe the activity of a novel cephalosporin, CXA-101 (FR26 4205), against a panel of highly resistant Pseudomonas aeruginosa isolates collected from U.S. hospitals. CXA-101 demonstrated increased potency against this population of resistant isolates, with activity that is 4- to 10-fold higher than that of comparator agents in each phenotypic category. The addition of tazobactam did not improve its activity. CXA-101 appears to be a promising addition to the category of antipseudomonal beta-lactams.

References

Dec 6, 2006·Antimicrobial Agents and Chemotherapy·Shinobu TakedaKazuo Hatano
Jul 24, 2007·International Journal of Antimicrobial Agents·Shinobu TakedaKeizo Yamaguchi
Jan 30, 2008·Pharmacotherapy·Anthony M NicasioDavid P Nicolau
Mar 11, 2008·Diagnostic Microbiology and Infectious Disease·Ronald N JonesPaul R Rhomberg
Aug 15, 2008·Bioorganic & Medicinal Chemistry Letters·Ayako TodaSatoshi Inoue
Feb 6, 2009·The Annals of Pharmacotherapy·Jared L CrandonDavid P Nicolau
Mar 3, 2009·Diagnostic Microbiology and Infectious Disease·Mariana CastanheiraDavid M Livermore
Mar 5, 2009·Antimicrobial Agents and Chemotherapy·José-Manuel Rodríguez-MartínezPatrice Nordmann
May 12, 2009·International Journal of Antimicrobial Agents·David M LivermoreMarina Warner

❮ Previous
Next ❯

Citations

Jun 13, 2012·The Journal of Antimicrobial Chemotherapy·Peter C Appelbaum
Jun 16, 2010·Antimicrobial Agents and Chemotherapy·Bartolomé MoyáAntonio Oliver
Aug 21, 2014·Expert Review of Anti-infective Therapy·Emilio MasedaFernando Gilsanz
Nov 16, 2010·International Journal of Antimicrobial Agents·Robert C Moellering
Jun 19, 2016·Annals of Clinical Microbiology and Antimicrobials·Christina A SutherlandDavid P Nicolau
Jun 22, 2016·Expert Opinion on Drug Metabolism & Toxicology·Florian M Wagenlehner, Jakhongir F Alidjanov
Mar 20, 2015·Clinical Microbiology Reviews·Xian-Zhi LiHiroshi Nikaido
Nov 11, 2015·Antimicrobial Agents and Chemotherapy·Alasdair P MacGowanKaren E Bowker
Nov 28, 2013·Antimicrobial Agents and Chemotherapy·David R SnydmanNilda V Jacobus
Dec 8, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David CluckJonathan Moorman
Oct 1, 2019·Current Opinion in Infectious Diseases·Christian M Gill, David P Nicolau
Feb 27, 2017·Blood Purification·Weerachai ChaijamornBruce A Mueller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.